Vanda’s social anxiety drug flunks Phase 3 trial in female patients
Vanda Pharmaceuticals said Wednesday it is putting its social anxiety disorder program on hold following a late-stage trial failure. The biotech’s drug, called VQW-765, missed the primary endpoint in a Phase ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.